Raymond James Resumes Coverage of Jazz Pharmaceuticals (JAZZ) With an Outperform Rating [Yahoo! Finance]
Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
jazzpharma.com
Company Research
Source: Yahoo! Finance
of Jazz Pharmaceuticals (NASDAQ:JAZZ) with an Outperform rating and set a price target of $227. The firm told investors that the Jazz story has travelled beyond the narrative of “it looks inexpensive/fairly valued, but where can I get upside?” since adding greater visibility to the tail value of the Epidiolex franchise and zanidatamab delivering “highly competitive” data in gastroesophageal adenocarcinoma. Jazz Pharmaceuticals plc (JAZZ): Among Billionaire Ray Dalio's Bridgewater's Stock Picks with Huge Upside Potential Jazz Pharmaceuticals (NASDAQ:JAZZ) also received a rating update from Piper Sandler on March 19, with the firm lifting the price target on the stock to $232 from $219 while maintaining an Overweight rating on the shares. The firm stated that moving further into 2026, it continues to view the company as undervalued at a current EV/2026E EBITDA of only seven times in the context of a company that has strong visibility into double-digit overall top-line growth startin
Show less
Read more
Impact Snapshot
Event Time:
JAZZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAZZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAZZ alerts
High impacting Jazz Pharmaceuticals plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JAZZ
News
- Jazz Pharmaceuticals (JAZZ) had its "overweight" rating reaffirmed by Barclays PLC.MarketBeat
- Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Strong Recent Returns And Oncology Pipeline Focus [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals Touts Record $4.3B 2025 Revenue, Reaffirms 2026 Outlook at Conference [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals plc (JAZZ) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Jazz Pharmaceuticals (JAZZ) was upgraded by Raymond James Financial, Inc. to "moderate buy".MarketBeat
JAZZ
Earnings
- 2/24/26 - Beat
JAZZ
Sec Filings
- 4/3/26 - Form 4
- 4/1/26 - Form 144
- 3/27/26 - Form SCHEDULE
- JAZZ's page on the SEC website